A Phase 2/3 interventional study of rVIII-SingleChain and Octocog alfa in Hemophilia A, sponsored by CSL Behring. Completed at 56 sites in 20 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-08-09.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing F8 protein, human in Hemophilia A — none open to participants now, none under way, none of them phase 3. F8 protein, human · Hemophilia A.
Among the 18 studies testing F8 protein, human in Hemophilia A, this one has the largest enrollment, is one of 2 that started in 2012, is one of 4 in phase 2/3, and was the 13th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →None of the 18 studies testing F8 protein, human in Hemophilia A is open now. The open studies under Hemophilia A, anywhere →
F8 protein, human: first FDA approval 1974 (Koate, Koate-Dvi), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2001; this study’s year is marked. 2 started in 2012.
This study's enrollment of 175 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 44 across the 18 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 18 have an industry lead sponsor. The 4 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
14 studies in Hemophilia A by CSL Limited: none open now, none under way, none of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 14 studies in Hemophilia A by CSL Limited, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 2 in phase 2/3, and was the 7th registered.
CSL Limited’s Hemophilia A studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing F8 protein, human in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among CSL Limited’s 14 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This is an open-label, non-randomized, efficacy, safety and pharmacokinetic (PK) study comparing octocog alfa and rVIII-SingleChain. The study consists of three parts, a PK period (Part 1), a continuation of dosing safety and efficacy period (Part 2) and a safety, efficacy, and repeat PK period (Part 3) and also includes a surgical sub-study for subjects enrolled in Parts 2 and 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: rVIII-SingleChain · Biological: Octocog alfa
In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
Also known as: Recombinant Factor VIII (rFVIII), CSL627
In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
Also known as: Human coagulation factor VIII (rDNA)
Treatment Success
The investigator rated the efficacy of the treatment based on a 4-point rating scale "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point; the percentage of bleeding events with a rating of excellent or good and the 95% confidence interval are presented. The denominator includes all treated bleeding events. The 95% confidence interval is based on a model to account for within-subject correlation.
Time frame: Up to 24 months
Inhibitor Formation to FVIII
Number of subjects who develop inhibitors to FVIII
Time frame: Up to 24 months
Annualized Spontaneous Bleeding Rate
The annualized spontaneous bleeding rate (AsBR) was derived for each subject as follows: 365.25\*(number of spontaneous bleeding episodes requiring treatment) / (observed treatment period of interest).
Time frame: Up to 24 months
Treatment Success During the Peri-operative Surgical Sub-study
Subjects received rVIII-SingleChain before and during surgery based on the type of surgery and the clinical status of the subject. The investigator rated the efficacy of the treatment based on a 4-point surgical treatment rating scale of "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point. The rate of success, defined as the percentage of surgeries with a rating of excellent or good for hemostatic efficacy on the surgical treatment scale is presented for the Surgical Population, based on the total number of surgeries (N=16) as denominator.
Time frame: From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)
AUC0-∞ (Part 1)
AUC0-∞ (AUC from 0 extrapolated to infinity) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion
Cmax (Part 1)
Cmax of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion
Tmax (Part 1)
Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after a single infusion of octocog alfa and rVIII-SingleChain.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion
Half-life (t1/2) (Part 1)
Half-life (t1/2) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion.
Mean Residence Time (MRT) (Part 1)
Mean residence time (MRT) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion
Clearance (Cl) (Part 1)
Clearance (Cl) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion
Volume of Distribution at Steady-state (Vss) (Part 1)
Volume of distribution at steady-state (Vss) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
Time frame: Before infusion and at up to 10 time points within 72 hours of infusion
Incremental Recovery (Part 1)
Incremental recovery of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
Time frame: At 30 minutes after infusion
Annualized Bleeding Rate for Total Bleeds and Traumatic Bleeds
The annualized bleeding rate was derived for each subject as follows: 365.25\*(number of bleeding episodes requiring treatment) / (observed treatment period of interest).
Time frame: Up to 24 months
Proportion of Bleeding Episodes Requiring 1, 2, 3 or > 3 Infusions of rVIII-SingleChain to Achieve Hemostasis
Percentage of bleeding episodes requiring 1, 2, 3 or \> 3 infusions of rVIII-SingleChain to achieve hemostasis. The denominator includes all treated bleeding episodes.
Time frame: During the study (up to 24 months; assessed at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24)
Incremental Recovery (Part 3)
Incremental recovery of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.
Time frame: At 30 minutes after infusion
Volume of Distribution at Steady-state (Vss) (Part 3)
Volume of distribution at steady-state (Vss) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.
Clearance (Cl) (Part 3)
Clearance (Cl) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.
Mean Residence Time (MRT) (Part 3)
Mean residence time (MRT) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.
Half-life (t1/2) (Part 3)
Half-life (t1/2) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.
Tmax (Part 3)
Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after an initial and repeat infusion of rVIII-SingleChain.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.
Cmax (Part 3)
Cmax of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion
AUC0-∞ (Part 3)
AUC0-∞ (AUC from 0 extrapolated to infinity) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
Time frame: Before infusion and at up to 12 time points within 96 hours of infusion
This multicenter, multinational study enrolled subjects at 54 participating study centers in the United States, Japan, Europe, Australia, Canada, Lebanon, Malaysia, Philippines, Russian Federation, South Africa, and Ukraine.
| Milestone | Recombinant Factor VIII (rFVIII) |
|---|---|
| Started | 174 |
| Completed | 161 |
| Not completed | 13 |
| Withdrew: Knee surgery (prior to surgery substudy) | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: 50 exposure days not reached | 2 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Subject did not reach 6 mo of treatment | 1 |
The investigator rated the efficacy of the treatment based on a 4-point rating scale "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point; the percentage of bleeding events with a rating of excellent or good and the 95% confidence interval are presented. The denominator includes all treated bleeding events. The 95% confidence interval is based on a model to account for within-subject correlation.
| % bleeding events successfully treated | rVIII-SingleChain On-demand | rVIII-SingleChain Prophylaxis | rVIII-SingleChain |
|---|---|---|---|
| Treatment Success | 92.4 (87.8 to 95.3) | 92.2 (86.3 to 95.8) | 92.3 (88.9 to 94.8) |
Number of subjects who develop inhibitors to FVIII
| participants | Recombinant Factor VIII (rFVIII) |
|---|---|
| Inhibitor Formation to FVIII | 0 |
The annualized spontaneous bleeding rate (AsBR) was derived for each subject as follows: 365.25\*(number of spontaneous bleeding episodes requiring treatment) / (observed treatment period of interest).
| Number of spontaneous bleeds per year | rVIII-SingleChain On-demand | rVIII-SingleChain Prophylaxis |
|---|---|---|
| Annualized Spontaneous Bleeding Rate | 11.73 (2.8 to 36.5) | 0.00 (0.0 to 2.4) |
Subjects received rVIII-SingleChain before and during surgery based on the type of surgery and the clinical status of the subject. The investigator rated the efficacy of the treatment based on a 4-point surgical treatment rating scale of "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point. The rate of success, defined as the percentage of surgeries with a rating of excellent or good for hemostatic efficacy on the surgical treatment scale is presented for the Surgical Population, based on the total number of surgeries (N=16) as denominator.
| % of surgeries with successful treatment | rVIII-SingleChain Surgical |
|---|---|
| Treatment Success During the Peri-operative Surgical Sub-study | 100 |
AUC0-∞ (AUC from 0 extrapolated to infinity) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
| IU*h/dL | PK Population (Part 1) |
|---|---|
| Octocog alfa | 1550 ± 552 |
| rVIII-SingleChain | 2090 ± 650 |
Cmax of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
| IU/dL | PK Population (Part 1) |
|---|---|
| Octocog alfa | 116 ± 18.1 |
| rVIII-SingleChain | 113 ± 17.4 |
Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after a single infusion of octocog alfa and rVIII-SingleChain.
| hours | PK Population (Part 1) |
|---|---|
| Octocog alfa | 0.583 (0.450 to 0.800) |
| rVIII-SingleChain | 0.683 (0.467 to 1.25) |
Half-life (t1/2) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| hours | PK Population (Part 1) |
|---|---|
| Octocog alfa | 13.3 ± 4.36 |
| rVIII-SingleChain | 14.5 ± 3.77 |
Mean residence time (MRT) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| hours | PK Population (Part 1) |
|---|---|
| Octocog alfa | 17.1 ± 5.57 |
| rVIII-SingleChain | 20.4 ± 5.49 |
Clearance (Cl) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
| mL/h/kg | PK Population (Part 1) |
|---|---|
| Octocog alfa | 3.68 ± 1.41 |
| rVIII-SingleChain | 2.64 ± 0.846 |
Volume of distribution at steady-state (Vss) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
| mL/kg | PK Population (Part 1) |
|---|---|
| Octocog alfa | 57.1 ± 11.3 |
| rVIII-SingleChain | 50.0 ± 7.51 |
Incremental recovery of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.
| [IU/dL]/[IU/kg] | PK Population (Part 1) |
|---|---|
| Octocog alfa | 2.32 ± 0.381 |
| rVIII-SingleChain | 2.24 ± 0.357 |
The annualized bleeding rate was derived for each subject as follows: 365.25\*(number of bleeding episodes requiring treatment) / (observed treatment period of interest).
| Number of bleeds per year | rVIII-SingleChain On-demand | rVIII-SingleChain Prophylaxis |
|---|---|---|
| Total Bleeds | 19.64 (6.2 to 46.5) | 1.14 (0.0 to 4.2) |
| Traumatic Bleeds | 3.12 (0.0 to 8.4) | 0.00 (0.0 to 0.9) |
Percentage of bleeding episodes requiring 1, 2, 3 or \> 3 infusions of rVIII-SingleChain to achieve hemostasis. The denominator includes all treated bleeding episodes.
| Percentage of bleeding episodes | rVIII-SingleChain On-demand | rVIII-SingleChain Prophylaxis | rVIII-SingleChain |
|---|---|---|---|
| Requiring 1 infusion for hemostasis | 82.7 | 76.7 | 80.9 |
| Requiring 2 infusions for hemostasis | 12.0 | 14.0 | 12.6 |
| Requiring 3 infusions for hemostasis | 3.22 | 3.88 | 3.42 |
| Requiring >3 infusions for hemostasis | 2.03 | 5.43 | 3.07 |
Incremental recovery of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.
| [IU/dL]/[IU/kg] | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 63 | 1.85 ± 0.404 |
| Repeat, n = 29 | 1.99 ± 0.352 |
Volume of distribution at steady-state (Vss) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| mL/kg | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 64 | 59.5 ± 14.2 |
| Repeat, n = 30 | 53.1 ± 8.74 |
Clearance (Cl) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| mL/h/kg | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 64 | 3.15 ± 1.21 |
| Repeat, n = 30 | 3.05 ± 1.1 |
Mean residence time (MRT) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| hours | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 64 | 20.3 ± 5.36 |
| Repeat, n = 30 | 18.9 ± 5.39 |
Half-life (t1/2) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| hours | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 64 | 14.1 ± 3.82 |
| Repeat, n = 30 | 12.9 ± 3.7 |
Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after an initial and repeat infusion of rVIII-SingleChain.
| hours | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 63 | 0.333 (0.117 to 1.22) |
| Repeat, n = 29 | 0.317 (0.117 to 0.667) |
Cmax of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.
| IU/dL | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 63 | 99.9 ± 19.9 |
| Repeat, n = 29 | 108 ± 18.5 |
AUC0-∞ (AUC from 0 extrapolated to infinity) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.
| IU*h/dL | rVIII-SingleChain PK Population (Part 3) |
|---|---|
| Initial, n = 64 | 1830 ± 640 |
| Repeat, n = 30 | 1880 ± 649 |
Collected over For the duration of the study, approximately 2 years, 10 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population | — | 8/174 (4.6%) | 45/174 (25.9%) |
| Event | Safety Population |
|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 1/174 |
| Blood uric acid increasedInvestigations | 1/174 |
| Tonsillar haemorrhageRespiratory, thoracic and mediastinal disorders | 1/174 |
| HypersensitivityImmune system disorders | 1/174 |
| AnaemiaBlood and lymphatic system disorders | 1/174 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/174 |
| Suicidal ideationPsychiatric disorders | 1/174 |
| Varices oesophagealGastrointestinal disorders | 1/174 |
| Postoperative wound infectionInfections and infestations | 1/174 |
| Viral infectionInfections and infestations | 1/174 |
| Event | Safety Population |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 20/174 |
| NasopharyngitisInfections and infestations | 18/174 |
| HeadacheNervous system disorders | 13/174 |
| Age, Continuous(years) | Recombinant Factor VIII (rFVIII) |
|---|---|
| Mean | 31.3 ± 11.77 |
| Age, Customized(participants) | Recombinant Factor VIII (rFVIII) |
|---|---|
| Adolescents (12-17 years) | 14 |
| Adults (18-65 years) | 160 |
| Sex: Female, Male(Participants) | Recombinant Factor VIII (rFVIII) |
|---|---|
| Female | 0 |
| Male | 174 |
| Type of FVIII product used before enrollment(participants) | Recombinant Factor VIII (rFVIII) |
|---|---|
| Plasma-derived Product | 83 |
| Recombinant Product | 91 |
| Treatment modality of FVIII therapy before enrollment(participants) | Recombinant Factor VIII (rFVIII) |
|---|---|
| Prophylaxis | 82 |
| On-demand | 92 |
The record gives a start of Feb 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 8 months after primary completion. A results delay was requested in Dec 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lonoctocog alfa · F8 protein, human